These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32636543)

  • 1. The Feds Act to Boost Competition in the Biosimilars Market.
    Miller HI
    Mo Med; 2020; 117(3):196-198. PubMed ID: 32636543
    [No Abstract]   [Full Text] [Related]  

  • 2. Business of biosimilars - 14th annual conference (October 15-17, 2013 - Boston, Massachusetts, USA).
    Bourgoin A
    Drugs Today (Barc); 2013 Dec; 49(12):799-801. PubMed ID: 24524098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars Ready, At Last, To Make Their Entrance: Stars Are Born or Do They Fizzle?
    Reinke T
    Manag Care; 2017 Mar; 26(3):20-23. PubMed ID: 28510515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bullying biosimilars: cheaper drugs stymied in USA.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
    [No Abstract]   [Full Text] [Related]  

  • 5. First monoclonal antibody biosimilars: tackling the challenge of substitution.
    Bocquet F; Paubel P
    J Med Econ; 2016 Jun; 19(6):645-7. PubMed ID: 27080815
    [No Abstract]   [Full Text] [Related]  

  • 6. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competition in the Age of Biosimilars.
    Chandra A; Vanderpuye-Orgle J
    JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179
    [No Abstract]   [Full Text] [Related]  

  • 8. Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition.
    San-Juan-Rodriguez A; Gellad WF; Good CB; Hernandez I
    JAMA Netw Open; 2019 Dec; 2(12):e1917379. PubMed ID: 31834391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why Are Biosimilars Not Living up to Their Promise in the US?
    Zhai MZ; Sarpatwari A; Kesselheim AS
    AMA J Ethics; 2019 Aug; 21(8):E668-678. PubMed ID: 31397662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Biosimilar Pipeline Seams Seem To Be Bursting.
    Reinke T
    Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.
    Farhat F; Torres A; Park W; de Lima Lopes G; Mudad R; Ikpeazu C; Abi Aad S
    Oncologist; 2018 Mar; 23(3):346-352. PubMed ID: 29284760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
    Farfan-Portet MI; Gerkens S; Lepage-Nefkens I; Vinck I; Hulstaert F
    Eur J Health Econ; 2014 Apr; 15(3):223-8. PubMed ID: 24271016
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic implications of biosimilars.
    Singh SC; Bagnato KM
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars of low-molecular-weight heparin products: fostering competition or reducing 'biodiversity'?
    Harenberg J; Cimminiello C; Agnelli G; Di Minno G; Polo Friz H; Prandoni P; Scaglione F
    J Thromb Haemost; 2016 Mar; 14(3):421-6. PubMed ID: 26711899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incentives for market penetration of biosimilars in Belgium and in five European countries.
    Swartenbroekx N; Farfan-Portet ; Espín J; Gerkens S
    J Pharm Belg; 2014 Dec; (4):36-46. PubMed ID: 25562926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Can we transfer the mechanisms of the generics market to biosimilars?].
    Jacke CO; Wild F
    Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarket policy considerations for biosimilar oncology drugs.
    Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
    Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.